CLINICAL TRIALS PROFILE FOR HEPATITIS B VACCINE (RECOMBINANT)

All Clinical Trials for hepatitis b vaccine (recombinant)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00100633 ↗	Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1/Phase 2	2004-12-01	The purpose of the study is to determine the safety of and immune response to a hepatitis B virus vaccine series given with a boosting agent, CpG7909 oligodeoxynucleotides (ODN), in HIV infected and HIV uninfected individuals who previously failed to develop a response to hepatitis B vaccine. Study hypothesis: Administration of CpG7909 ODN together with recombinant hepatitis B vaccine will result in increased frequency and magnitude of response to vaccine in individuals who have previously failed to mount a response to vaccination, and that in HIV infected subjects with detectable plasma viremia, it will lead to the enhancement of HIV-specific responses.
NCT00114621 ↗	Anthrax Vaccine Clinical Trials	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	2004-09-08	This study will examine the recombinant, that is, produced by genetic engineering, protective antigen (rPA) that brings about antibodies to neutralize the anthrax toxin and that could therefore be predicted to offer protection against anthrax. Today, anthrax is rarely encountered in the United States, since the introduction of vaccines for cattle in the 1930s. A human vaccine was licensed in 1970. Vaccination against anthrax has been confined to people at risk, such as wool sorters and some veterinarians. However, the rising prospects of B. anthracis being used as a weapon have led to routine administration of the anthrax vaccine to members of the armed forces. Adults who are in good health may be eligible for this study. The involvement of 300 adults is planned. Participants will have a general physical exam and test for vital signs. There will also be collection of blood for chemistry and hematology; urinalysis; tests for HIV, hepatitis B and C, and liver function; and a pregnancy test, if applicable. On a random basis, patients will receive one of the rPA formulations. Two doses of rPA will be evaluated, 10 microgram ((Micro)g) and 20 (Micro)g. This evaluation aims to establish the safety and most desirable level of dosage. Patients will receive one injection of the vaccine, administered in the left shoulder or left thigh. About 30 minutes later, their temperature will be taken, and the injection site will be inspected. Rare but severe reactions could occur if there is extreme sensitivity to a vaccine. However, such an occurrence is extremely rare following a vaccine, and if there are any dangerous symptoms, they can be effectively treated by medications available to patients while they are at the clinic. If there are no significant abnormal results, patients may return home. About 6 hours later and daily for 7 days, they will take their temperature and examine the injection site. The vaccine may cause temporary discomfort at the site of injection, and participants may experience a mild fever for 1 or 2 days after vaccination. Patients will receive diary cards, a digital thermometer, and instructions on taking their temperature and measuring redness and swelling at the injection site, as well as for recording aches, muscle pain, or sensitivity to light for 7 days. They will be examined at the clinic at 72 hours following vaccination and also on the 7th day if they have a fever at or above 100.4 , if swelling is at or more than 2 inches, or if they request an exam. Meanwhile, a clinic staff member will call patients and discuss the findings. Then patients will receive a second and third injection of the same vaccine at 2-month intervals. There will also be interviews about patients' health at each visit to the clinic, plus monitoring of the vaccination after 6 hours and for 7 days. One year later, patients will receive a fourth injection of the same vaccine. Direct benefit to participants in this study is not guaranteed, although an antibody response is predicted. The results in this study will help in the development of improved vaccines for anthrax.
NCT00924092 ↗	An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing	Completed	National Cancer Institute (NCI)	Phase 1	2009-03-13	Objectives: - To find out the maximum tolerated dose of the GI-6207 vaccine (the highest dose that does not cause unacceptable side effects), and to evaluate any side effects. - To see if GI-6207 has any effect on patients tumors. - To learn how the vaccine causes immune responses against the cancer. Eligibility: - Patients 18 years of age and older who have been diagnosed with a cancer that has not responded to standard treatments. Patients must not be allergic to yeast or yeast products. Design: - Initial physical examination, blood and tissue sampling, computed tomography (CT) scan, and skin test to determine eligibility for the procedure. - Treatment with GI-6027 in seven 14-day cycles as follows: - Vaccine administered on days 1, 15, 29, 43, 57, 71, and 85. - Vaccine given at four sites around the body: right and left chest area below the armpit, and right and left upper thigh in the pelvic region. (These areas drain into parts of your body that contain large numbers of lymph nodes. The lymph nodes contain immune cells that may be activated by the vaccine to target cancer cells.) - Clinic visits for physical examinations to check vital signs, take additional blood and urine samples, and perform other tests needed for the study. - After day 85 (about 3 months), patients will continue to receive vaccine monthly (or every 28 days) as long as the vaccine is not producing harmful effects or side effects and the cancer is either stable or reducing. Patients who do well on the vaccine may continue to receive it for as long as it is available.
NCT01412567 ↗	Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers	Completed	Indian Council of Medical Research	N/A	2005-10-01	Prevention of perinatal transmission is essential to decrease the global burden of chronic HBV. Recombinant HBV vaccine and hepatitis B immunoglobulin (HBIG) given after delivery to the newborns of HBsAg positive mothers is the standard of care for prevention of HBV in babies. Some studies have however, shown that vaccine alone may be equally effective. Hence, immunoprophylaxis with hepatitis B vaccine with or without HBIG is effective in prevention of transmission of overt HBV infection to the babies. The primary outcome measure of most of the trials on immunoprophylaxis was the occurrence of hepatitis B, defined as a blood specimen positive for hepatitis B surface antigen (HBsAg). However, whether this immunoprophylaxis also prevents HBsAg negative HBV infection (occult HBV infection) in babies is not known. In the present study the investigators evaluated the efficacy of the two regimens; vaccination alone and compared it with vaccination plus HBIG administration at birth in preventing transmission of both overt and occult HBV infection to the newborn babies.
NCT01412567 ↗	Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers	Completed	Lady Hardinge Medical College	N/A	2005-10-01	Prevention of perinatal transmission is essential to decrease the global burden of chronic HBV. Recombinant HBV vaccine and hepatitis B immunoglobulin (HBIG) given after delivery to the newborns of HBsAg positive mothers is the standard of care for prevention of HBV in babies. Some studies have however, shown that vaccine alone may be equally effective. Hence, immunoprophylaxis with hepatitis B vaccine with or without HBIG is effective in prevention of transmission of overt HBV infection to the babies. The primary outcome measure of most of the trials on immunoprophylaxis was the occurrence of hepatitis B, defined as a blood specimen positive for hepatitis B surface antigen (HBsAg). However, whether this immunoprophylaxis also prevents HBsAg negative HBV infection (occult HBV infection) in babies is not known. In the present study the investigators evaluated the efficacy of the two regimens; vaccination alone and compared it with vaccination plus HBIG administration at birth in preventing transmission of both overt and occult HBV infection to the newborn babies.
NCT01412567 ↗	Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers	Completed	Govind Ballabh Pant Hospital	N/A	2005-10-01	Prevention of perinatal transmission is essential to decrease the global burden of chronic HBV. Recombinant HBV vaccine and hepatitis B immunoglobulin (HBIG) given after delivery to the newborns of HBsAg positive mothers is the standard of care for prevention of HBV in babies. Some studies have however, shown that vaccine alone may be equally effective. Hence, immunoprophylaxis with hepatitis B vaccine with or without HBIG is effective in prevention of transmission of overt HBV infection to the babies. The primary outcome measure of most of the trials on immunoprophylaxis was the occurrence of hepatitis B, defined as a blood specimen positive for hepatitis B surface antigen (HBsAg). However, whether this immunoprophylaxis also prevents HBsAg negative HBV infection (occult HBV infection) in babies is not known. In the present study the investigators evaluated the efficacy of the two regimens; vaccination alone and compared it with vaccination plus HBIG administration at birth in preventing transmission of both overt and occult HBV infection to the newborn babies.

Clinical Trial Conditions for hepatitis b vaccine (recombinant)

Condition Name

Condition Name for hepatitis b vaccine (recombinant)
Intervention	Trials
Malaria,Falciparum	2
Chronic Hepatitis B	2
Hepatitis B	1
HIV Infection	1

Condition MeSH

Condition MeSH for hepatitis b vaccine (recombinant)
Intervention	Trials
Hepatitis B	3
Malaria	2
HIV Infections	2
Hepatitis, Chronic	2

Clinical Trial Locations for hepatitis b vaccine (recombinant)

Trials by Country

Trials by Country for hepatitis b vaccine (recombinant)
Location	Trials
United States	4
Nepal	2
Burkina Faso	2
Mali	2
India	1

Trials by US State

Trials by US State for hepatitis b vaccine (recombinant)
Location	Trials
Maryland	2
District of Columbia	1
Ohio	1

Clinical Trial Progress for hepatitis b vaccine (recombinant)

Clinical Trial Phase

Clinical Trial Phase for hepatitis b vaccine (recombinant)
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for hepatitis b vaccine (recombinant)
Clinical Trial Phase	Trials
Completed	7
Unknown status	1
Active, not recruiting	1

Clinical Trial Sponsors for hepatitis b vaccine (recombinant)

Sponsor Name

Sponsor Name for hepatitis b vaccine (recombinant)
Sponsor	Trials
Institut de Recherche en Sciences de la Sante, Burkina Faso	2
Malaria Research and Training Center, Bamako, Mali	2
London School of Hygiene and Tropical Medicine	2

Sponsor Type

Sponsor Type for hepatitis b vaccine (recombinant)
Sponsor	Trials
Other	15
NIH	3

Hepatitis B Vaccine (Recombinant): Clinical Trials, Market Analysis, and Projections

Last updated: February 19, 2026

Current Clinical Trial Landscape for Recombinant Hepatitis B Vaccines

The development of recombinant Hepatitis B vaccines continues to evolve, with ongoing clinical trials focusing on improving immunogenicity, expanding target populations, and exploring novel delivery mechanisms. Current research centers on several key areas:

• Enhanced Immunogenicity: Trials are evaluating vaccine formulations designed to elicit stronger and more durable immune responses, particularly in specific patient groups like immunocompromised individuals and the elderly. This includes studies on adjuvants, antigen modifications, and optimized dosing schedules.
• Pediatric and Adolescent Vaccination: While existing vaccines are well-established for these age groups, some trials aim to assess the efficacy and safety of newer recombinant formulations or alternative vaccination schedules to maximize long-term protection.
• Therapeutic Vaccines: A distinct but related area of research involves therapeutic vaccines intended to boost immune responses in individuals already infected with Hepatitis B virus (HBV), aiming to achieve functional cure. These trials are distinct from prophylactic vaccines.
• Combination Vaccines: Studies are exploring the co-administration of recombinant Hepatitis B vaccines with other vaccines to streamline immunization schedules and improve convenience.

Key Clinical Trial Registries and Data Sources:

• ClinicalTrials.gov: The primary repository for publicly accessible clinical trial information, listing over 1,000 studies related to Hepatitis B vaccines. [1]
• WHO International Clinical Trials Registry Platform (ICTRP): Provides access to clinical trial data from multiple registries worldwide. [2]
• European Medicines Agency (EMA) & U.S. Food and Drug Administration (FDA) Databases: Contain approved vaccine information and publicly available assessment reports.

Examples of Ongoing Research Trends:

• Novel Adjuvants: Investigating adjuvants like AS01, AS02, and CpG oligonucleotides to enhance antigen presentation and immune cell activation.
• Alternative Delivery Routes: While intramuscular injection remains standard, research into intradermal or needle-free delivery systems is ongoing, with potential benefits for patient comfort and potentially different immune responses.
• Long-Term Immunogenicity Studies: Tracking antibody levels and T-cell responses over extended periods to assess the duration of protection offered by new or modified vaccine regimens.

Market Analysis for Recombinant Hepatitis B Vaccines

The global market for recombinant Hepatitis B vaccines is characterized by established players, significant public health initiatives, and a consistent demand driven by vaccination programs worldwide.

Market Size and Growth Drivers:

The market is projected to reach an estimated USD 3.8 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2023 to 2028. [3]

• Global Vaccination Programs: The World Health Organization's (WHO) Global Hepatitis Strategy aims to eliminate viral hepatitis as a public health threat by 2030. This initiative drives demand for widespread HBV vaccination. [4]
• Increasing Awareness and Screening: Growing awareness of Hepatitis B infection risks and expanded screening programs in endemic and non-endemic regions contribute to vaccine uptake.
• High Prevalence in Developing Nations: Regions with a high prevalence of Hepatitis B, such as parts of Asia and Africa, represent significant markets due to the need for universal infant vaccination and catch-up campaigns.
• Technological Advancements: Ongoing research and development leading to improved vaccine efficacy, reduced side effects, and novel delivery methods can spur market growth.

Key Market Segments:

• By End-User:
  • Hospitals and Clinics: The largest segment due to routine vaccination schedules.
  • Government and Public Health Organizations: Major purchasers for national immunization programs.
  • Research Institutes: For clinical trials and academic research.
• By Age Group:
  • Infants and Children: The primary target group for prophylactic vaccination.
  • Adults: For catch-up vaccination and individuals at high risk (e.g., healthcare workers, pregnant women, travelers).
• By Geography:
  • Asia Pacific: Dominates the market due to high prevalence and large populations in countries like China and India. [3]
  • North America & Europe: Mature markets with established vaccination programs and high per capita consumption.
  • Latin America & Middle East/Africa: Growing markets with increasing focus on public health and vaccination coverage.

Competitive Landscape:

The market is highly competitive, with several major pharmaceutical companies holding significant market share.

Leading Manufacturers of Recombinant Hepatitis B Vaccines:

• GlaxoSmithKline (GSK): Known for its Engerix-B® vaccine.
• Merck & Co., Inc.: Offers the Recombivax HB® vaccine.
• Sanofi Pasteur: A major player with a comprehensive vaccine portfolio.
• Dynavax Technologies Corporation: Developing novel HBV vaccine candidates.
• CanSinoBIO: A significant manufacturer in the Chinese market.

Market Challenges:

• Price Sensitivity: In public health programs, particularly in lower-income countries, price remains a critical factor.
• Cold Chain Requirements: Maintaining the efficacy of vaccines necessitates robust cold chain infrastructure, which can be a logistical challenge in some regions.
• Emerging Viral Variants: While less common for HBV compared to some other viruses, the potential for viral evolution and its impact on vaccine effectiveness is a long-term consideration.
• Competition from Biosimilars: As patents expire, the potential for biosimilar competition could impact pricing and market dynamics.

Market Projections and Future Trends

The future of the recombinant Hepatitis B vaccine market is shaped by evolving public health strategies, advancements in vaccine technology, and the persistent global burden of Hepatitis B infection.

Projected Market Growth Factors:

• Universal Vaccination Mandates: Continued enforcement and expansion of universal infant HBV vaccination policies globally will sustain baseline demand.
• Catch-Up Vaccination Campaigns: Efforts to reach unvaccinated populations, particularly in high-prevalence countries, will create significant growth opportunities.
• Therapeutic Vaccine Development: Successful development and commercialization of therapeutic HBV vaccines could open a new market segment targeting chronic carriers, aiming for functional cure.
• Combination Vaccine Introduction: The introduction of vaccines that combine HBV with other antigens (e.g., DTaP-IPV-HepB) can simplify immunization schedules and enhance market penetration.
• Focus on High-Risk Groups: Increased emphasis on vaccinating specific high-risk adult populations, including immunocompromised individuals and those undergoing dialysis, will contribute to market expansion.
• Technological Innovations:
  • mRNA Vaccine Technology: While currently less prevalent for HBV compared to other infectious diseases, the success of mRNA technology in other areas may lead to its exploration for HBV vaccines, potentially offering faster development and manufacturing.
  • Improved Adjuvants and Delivery Systems: Continued innovation in these areas can lead to vaccines with enhanced efficacy and patient compliance.

Geographic Market Shifts:

• Asia Pacific: Expected to remain the largest market due to its large population, ongoing public health investments, and high HBV endemicity.
• Africa: Projected to experience significant growth driven by increasing healthcare infrastructure and government commitment to vaccination programs.
• Emerging Markets: Growing economies in Latin America and Southeast Asia will present opportunities as vaccination coverage expands.

Potential Disruptors:

• Eradication of HBV: While a long-term aspiration, the eventual global eradication of HBV would fundamentally alter the market.
• Breakthrough Treatments for Chronic HBV: The development of highly effective curative treatments could reduce the long-term reliance on prophylactic vaccination in some contexts, although vaccination would remain critical for prevention.
• Unforeseen Public Health Crises: Pandemics or other global health emergencies can shift resource allocation and impact routine immunization programs, potentially affecting market dynamics in the short to medium term.

Key Strategic Considerations for Stakeholders:

• Investment in R&D: Continued focus on developing vaccines with improved immunogenicity, longer duration of protection, and suitability for diverse patient populations.
• Partnerships and Collaborations: Strategic alliances with governments, NGOs, and research institutions are crucial for market access and program implementation, particularly in low-resource settings.
• Manufacturing and Supply Chain Optimization: Ensuring robust and scalable manufacturing capabilities to meet global demand, while also addressing cold chain logistics.
• Market Access and Affordability: Developing pricing strategies that balance profitability with the need for accessibility in public health programs.
• Navigating Regulatory Pathways: Understanding and adapting to evolving regulatory requirements in different geographic markets.

The recombinant Hepatitis B vaccine market is expected to maintain a steady growth trajectory, underpinned by global health priorities and ongoing scientific advancements. The focus will increasingly be on enhancing vaccine performance and expanding access to achieve the ambitious goals of HBV elimination.

Key Takeaways

• The global market for recombinant Hepatitis B vaccines is projected to reach USD 3.8 billion by 2028, with a CAGR of 4.2% (2023-2028).
• Market growth is driven by WHO's Global Hepatitis Strategy, increasing awareness, high prevalence in developing nations, and technological advancements.
• Asia Pacific is the dominant market, with significant growth anticipated in Africa.
• Key manufacturers include GSK, Merck, and Sanofi Pasteur.
• Future trends include the development of therapeutic vaccines, combination vaccines, and advancements in mRNA technology.
• Challenges include price sensitivity, cold chain logistics, and the potential for emerging viral variants.

Frequently Asked Questions

1. What is the current regulatory status of therapeutic Hepatitis B vaccines in major markets like the US and EU?
2. How do recombinant Hepatitis B vaccines differ in their immunogenicity profiles across various age groups and immunocompromised populations?
3. What are the primary challenges in establishing and maintaining a robust cold chain for Hepatitis B vaccines in resource-limited settings?
4. What is the estimated market share of the top three manufacturers of recombinant Hepatitis B vaccines globally?
5. Are there any significant clinical trials underway evaluating the use of non-adjuvanted recombinant Hepatitis B vaccines for specific patient cohorts?

Citations

[1] ClinicalTrials.gov. (n.d.). Hepatitis B Vaccines. Retrieved from https://clinicaltrials.gov/search/condition/hepatitis-b%20vaccine

[2] World Health Organization. (n.d.). International Clinical Trials Registry Platform (ICTRP). Retrieved from https://www.who.int/clinical-trials-registry-platform

[3] Grand View Research. (2023). Hepatitis B Vaccines Market Size, Share & Trends Analysis Report By Type (Recombinant, Plasma-Derived), By Age Group (Infants, Adults), By End-use (Hospitals, Clinics, Government), By Region, And Segment Forecasts, 2023 - 2030.

[4] World Health Organization. (2022). Global Hepatitis Strategy 2022-2030: Towards Viral Hepatitis Elimination. Retrieved from https://www.who.int/publications/i/item/9789240050715